

Type II Toxin-Antitoxin Systems in *Escherichia coli*

He Zhang¹, Shuan Tao², Huimin Chen², Yewei Fang², Yao Xu³, A-Xiang Han², Fang Ma^{1,*}, Wei Liang^{2,*}

¹Department of Medical Laboratory, Bengbu Medical University, Bengbu, Anhui, People's Republic of China; ²Department of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China; ³School of Medicine, Ningbo University, Ningbo, Zhejiang, People's Republic of China

*These authors contributed equally to this work

Correspondence: Wei Liang, Department of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, 31 Liuting Street, Ningbo, Zhejiang, People's Republic of China, Tel +8613306652821, Fax +86-051885213100, Email hslwys@163.com; Fang Ma, Department of Medical Laboratory, Bengbu Medical University, No. 2600, Donghai Avenue, Bengbu, Anhui, People's Republic of China, Tel +8618955222802, Email 0600130@bbmc.edu.cn

Abstract: The toxin-antitoxin (TA) system is widespread in prokaryotes and archaea, comprising toxins and antitoxins that counter-balance each other. Based on the nature and mode of action of antitoxins, they are classified into eight groups (type I to VIII). Both the toxins and the antitoxins are proteins in type II TA systems, and the antitoxin gene is usually upstream of the toxin gene. Both genes are organized in an operon and expression of which is regulated at the transcriptional level by the antitoxin-toxin complex, which binds the operon DNA through the DNA-binding domain of the antitoxin. The TA system plays a crucial role in various cellular processes, such as programmed cell death, cell growth, persistence, and virulence. Currently, Type II TA systems have been used as a target for developing new antibacterial agents for treatment. Therefore, the focus of this review is to understand the unique response of Type II TA in *Escherichia coli* to stress and its contribution to the maintenance of resistant strains. Here, we review the Type II TA system in *E. coli* and describe their regulatory mechanisms and biological functions. Understanding how TA promotes phenotypic heterogeneity and pathogenesis mechanisms may help to develop new treatments for infections caused by pathogens rationally.

Keywords: *E. coli*, type II toxin-antitoxin, bacterial persistence, biofilm formation, phage infection

Introduction

TA systems are small genetic modules widely distributed in bacterial and archaeal genomes. Typically, the TA system is composed of toxins and antitoxins, and toxins are in most cases proteins that can influence DNA replication, transcription, protein synthesis, et al. Antitoxins may be RNA or proteins,¹ and under appropriate conditions, toxins can be prevented from performing their functions. Generally, toxins are relatively stable in structure, and antitoxins are relatively structurally unstable and are either rapidly degraded by intracellular proteases under stress or plasmid loss or down-regulated.² Initially, TA systems were identified in plasmids called plasmid maintenance systems. The first TA system identified was the plasmid-borne type II system, which plays a role in plasmid maintenance known as post-segregation killing.^{3,4} Once the plasmid encoding TA system is lost from a cell, it cannot produce the unstable antitoxin to neutralize the remaining stable toxin, and the growth of that cell is stunted, eventually leading to cell death. Later, many TA systems were also found on chromosomes.^{5–7} The toxins in the TA systems are all proteins (except the newly discovered type VIII system). Based on the nature of the antitoxin and its mode of action, the current types of antitoxins are as follows: type I antitoxins are sRNAs. Antitoxin sRNAs bind to the mRNA of the toxin to promote its degradation, impede the translation of the toxin, and inhibit the transcripts of its cognate toxins;^{8–13} Type II antitoxins exist under normal growth conditions as TA complexes, which are proteins that bind to homologous toxins and form neutralizing complexes;^{14–18} Type III antitoxins are also sRNAs, which bind homologous toxins and sequester them by forming neutralizing protein-RNA complexes;^{1,19–21} Type IV antitoxins are proteins. Acts on the cellular target of its toxin analog and protects or detoxifies the target rather instead of blocking the toxin itself;^{22,23} Type V RNase antitoxin prevents toxin accumulation

by specific degradation of its mRNAs;^{24,25} Type VI antitoxins are proteins that act as junctions, targeting their cognate toxins for degradation by ATP-dependent proteases;²⁶ Type VII antitoxins are proteins that are inactivated by post-translational modifications to their cognate toxins;^{27–29} Type VIII antitoxin is RNAs which inhibit the expression of their cognate RNA toxins and inhibit the transcription of the toxin or interact with the toxin RNA. Degradation of the toxin RNA or the recruitment of Cas proteins as transcriptional repressors by mimicking CRISPR RNAs.^{30,31} In addition to these well-defined types, some special cases have been described. For example, some modified toxins or antitoxins acting on cellular targets (types VII and IV, respectively) can form antitoxin-toxin protein complexes similar to type II systems,^{23,27} and some toxins can be associated with different types of antitoxins (type II and type IV) within the same maneuver.²²

Of these, type II TA systems are the most abundant and extensively studied, and each type II TA system is encoded by two small genes, which usually overlap by a few bases.^{32,33} The toxin and its cognate antitoxin form a stable TA complex that blocks the function of the toxin. Under stress conditions, the antitoxin can be degraded by proteases (for example, Lon, ClpAP, and ClpXP), and the toxin is released from the complex to exert a bacteriostatic effect. Because the antitoxin is not as stable as the toxin within the cell, the antitoxin has to be continuously produced to inhibit the toxin. In most cases, the type II antitoxin genes are located upstream of the toxin genes, so that antitoxins are produced before their cognate toxins, or they form small genomic islands of their own.^{34–36} However, upstream genes encode toxins in some special cases, such as *HigA/HigB*, *MqsR/YgiT*, and *MqsR/MqsA*.³⁷ In this review, we aim to provide an up-to-date overview of type II TA systems in *E. coli*, describe recent advances in these systems, and discuss research perspectives in this area.

Type II TA Systems in *E. coli*

Thousands of type II TA sites have been found in *E. coli*.⁶ In Type II TA systems, both the toxin and the antitoxins are small proteins. Antitoxins usually have two structural domains, one that binds DNA,^{14,38,39} and the other that binds and inhibits the activity of the cognate protein toxin¹⁴ (Figure 1). Antitoxins also often bind the promoters of their operons to repress transcription. In most cases, the toxins act as co-repressors. In some cases, they bind promoters of other genes. The type II TA system is regulated by marked differences in the cellular lifespan of antitoxins and toxins. That is, antitoxins are very sensitive to protein hydrolysis, whereas their cognate toxins are relatively stable. Thus, in response to




Figure 1 Type II toxin-antitoxin (TA) locus of *E. coli* K-12. Diagram of the genes and control loops of a typical type II TA locus. The red arrow to the right indicates the TA operon promoter. When the free toxin concentration is low, the promoter is repressed by the antitoxin during rapid growth, especially by the TA complex that binds tightly to the promoter region. In contrast, promoter activity is inhibited by free toxins, a regulatory phenomenon known as conditional synergy.

stress, antitoxins are selectively degraded. This leads to growth stagnation due to the effects of the toxins released on the cells. Many type II toxins are mRNA-disrupting enzymes (ribonucleic acid endonucleases) and are either ribosome-dependent (for example, *RelE*,^{40–42} *YoeB*,⁴³ *YafQ*,^{18,44} *YafO*,^{18,45} *HigB*^{46,47}) or ribosome-independent (for example, *YhaV*, *MazF*, *MqsR*,^{48–50} *ChpBK*, *HicA*, *PemK*).^{51,52} Another type II toxins inhibits DNA replication through interactions with DNA cleavage enzymes (for example, *CcdB*, *ParE*, *Doc*, and *HipA*) toxins act by phosphorylating elongation factors Tu and Glu-tRNA synthetase, respectively.^{39,53}

Target of Toxin Action

Currently, type II toxins are classified into nine superfamilies based on their structural features: *ParE/RelE*, *MazF*, *HicA*, *VapC*, *HipA*, *FicT/Doc*, *AtaT/TacT*, *Zeta* and *MbcT*. We summarize the toxin targets and mechanisms of action in Table 1. Toxins within a family may have various modes of action. For example, *ParE* toxin targets DNA gyrase, blocks the replication of DNA, and induces genome instability leading to cell death,^{54,55} while *RelE* has ribosome-dependent mRNA endonuclease activity. The toxin *CcdB* targets the GyrA subunit of the DNA gyrase, inhibiting DNA replication and causing DNA damage (Figure 2a). By inhibiting the DNA gyrase from catalyzing the rejoining of DNA in the cycle, *CcdB* locks the enzyme in the DNA into what is known as the cleavage complex, which works in a manner very similar to that of the quinolone antibiotics.⁵⁶ *CcdB* activity is thought to cause replication of the fork collapse, resulting in double-strand breaks, activation of the SOS response, and cell death. *Fic*, a type II toxin, targets DNA promoter and topoisomerase IV. It inhibits the ATP-hydrolyzing activity of DNA promoters, causing DNA damage and replication inhibition⁵⁷ (Figure 2a). Type II toxins, many of which are RNases with variable degrees of specificity, appear to have one major goal: to inhibit protein synthesis. For example, most toxins from the *MazF* family degrade free RNA with limited specificity, targeting mRNA and ribosomal RNA precursors⁵⁸ (Figure 2b). However, some *MazF* toxins are

Table 1 Targets of Action of Toxins and Their Mechanisms of Action

Toxin	Target of toxin action	Mechanisms of action of toxins	Reference
<i>CcdB</i>	replication	Inhibition of DNA rejoining in the cycle catalyzed by DNA gyrase	[56]
<i>Fic</i>		Inhibition of the ATP-hydrolyzing activity of DNA promoter and topoisomerase IV leads to DNA degradation or inhibition of replication	[57]
<i>SocB</i>		Interacts with the beta-sliding clamp of DNA polymerase and reduces the persistence of DNA replication	[26]
<i>ParE</i>		Inhibition of DNA gyrase	[64]
<i>RelE</i> , <i>HigB</i> , <i>YoeB</i> , <i>YafQ</i> , <i>MqsR</i> , <i>YafO</i>	translation	Cleaves ribosome-dependent mRNA	[65–67]
<i>MazF</i> , <i>YdcE</i> , <i>PemK</i> , <i>ChpBK</i>		Cleaves mRNA, rRNA, tRNA	[1,52,58]
<i>HicA</i> , <i>RelE</i>		Cleaves mRNA	[42]
<i>VapC</i>		Cleaves tRNA	[68]
<i>HipA</i>		Specific phosphorylation of aminoacyl-tRNA synthetase inhibits binding of specific tRNAs to amino acids	[60]
<i>Doc</i>		Phosphorylation and inactivation of elongation factor Tu (EF-Tu)	[53]
<i>MbcT</i>	Metabolic stress	Hydrolyze and deplete NAD ⁺	[61]
ζ , <i>PezT</i>	Cell wall synthesis	Phosphorylation of the peptidoglycan precursor uridine diphosphate-N-acetylglucosamine	[63]




Figure 2 The activity of toxins in the TA system. (a) Topoisomerase is inactivated by the amylase *FicT*, the DNA cleavage enzyme is poisoned by direct binding of *CcdB*. (b) Translation is the target of numerous toxins that act at every level of protein synthesis. *VapC* toxin cleaves the tRNA anticodon stem-loop or the stem-loop toxin loop of 23s ribosomal RNA. *MazF* toxin degrades free mRNA and ribosomal RNA, and *RelE* toxin cleaves translational mRNAs at the ribosomal A site. *HipA* toxin phosphorylates aminoacyl- tRNA synthetase and prevents tRNA charging. *Doc* phosphorylates elongation factors and prevents tRNA delivery to the ribosome. (c) *MbcT* toxin degrades NAD⁺. (d) ζ toxin phosphorylates precursors of peptidoglycan synthesis.

specific to a single species of tRNAs. In contrast, toxins of the *VapC* family specifically cleave the anticodon stem-loop⁵⁹ (Figure 2b), of different target tRNAs, and the sarcin-ricin loop of 23S rRNAs, which has structural similarity to the anticodon stem-loop. *RelE* and related toxins cleave mRNA in a co-translational way, entering the A site of the translating ribosome. mRNA cleavage usually occurs between positions 2 and 3 of the target codon. A variety of type II toxins affect tRNA function by modifying rRNAs or tRNA cofactors after they have been translated. *HipA* toxin selectively phosphorylates aminoacyl-tRNA synthetase and prevents the binding of particular tRNAs to amino acids⁶⁰ (Figure 2b). *Doc* toxin phosphorylates and inactivates the elongation factor Tu (EF-Tu), inhibiting tRNA presentation to the translating ribosome (Figure 2b). The type II *MbcT* toxin hydrolyzes and depletes NAD⁺, the primary electron carrier necessary for redox reactions.⁶¹ (Figure 2c). Type II ζ -toxin phosphorylates and depletes UDP-activated sugars, inhibiting the production of peptidoglycan and lipopolysaccharide, resulting in loss of cell wall integrity (Figure 2d). In a nutshell, toxins are ribonucleases, kinases, and acetyltransferases that, when overexpressed, prevent cell growth. The antitoxin binds to the active site of the homologous toxin and inhibits its activity. *MazE* binds to the active site of the homologous toxin and neutralizes its RNase activity. The binding of *RelB* to its cognate toxin results in the displacement of the c-terminal region necessary for toxin activity. ϵ and *PezA* spatially site-block ATP/GTP binding sites and inhibit the activity of their respective homologous toxin.^{62,63} However, few antitoxins inhibit the activity of their cognate toxin. For example, *HipB* inhibits homologous toxins by confirming that the toxin is in an inactive state. In conclusion, antitoxins inhibit toxin activity directly by binding to the active site and indirectly by binding to other sites.

Regulation of the Type II TA System

The TA system is normally tightly regulated to maintain a balanced “neutralized” state in the body. Under normal growth conditions, this regulation ensures that under stable conditions, the antitoxin exceeds the amount of its cognate toxin to inhibit its action.

Antitoxins of the type II TA system commonly contain DNA-binding and toxin-neutralizing domains.⁶⁹ The antitoxin-toxin complex binds to the operon and participates in the autoregulation of operon transcription. However, in some type II TA systems where the antitoxin lacks a DNA-binding domain and no transcriptional regulating mechanism is apparent, other factors outside the TA operon may influence the expression of toxin and antitoxin.

In a few cases, the antitoxin of the type II TA system is the only factor affecting the transcription of the operon. For example, in the *E. coli* HigBA system,⁶⁵ both the antitoxin HigA and the HigB-HigA complex bind the HigBA system operon with similar binding strength, indicating that antitoxin HigA binding to the operon is not affected by the toxin HigB. More complex is the regulatory mechanism of the DinJ/yafQ system associated with the SOS response in *E. coli*.⁷⁰ There are two promoters in the system, and the antitoxin DinJ binds the first promoter containing the LexA box, which regulates the transcription of the second promoter. LexA is a transcriptional repressor that plays a role in the SOS response.¹⁸ The SOS and TA-mediated stress responses and the link between them may represent a more comprehensive regulatory network when bacteria are under stress.

Typically, antitoxin alone binds the operon with low affinity, and the toxin acts as a co-deterrent to enhance the binding affinity of the antitoxin to the operon to form a more stable complex. In the *E. coli* VapBC system, the addition of toxin VapB resulted in tighter binding of antitoxin VapC to the operon.⁷¹

The toxin can affect the binding of the antitoxin to the promoter DNA of the TA system.⁷² In the MqsRA system of *E. coli*, the antitoxin MqsA contains two folded structural domains: an HTM-XRE structural domain that binds to the promoter DNA and a Zn²⁺-stabilizing structural domain that is used to neutralize the toxin MqsR. Due to the partial overlap of the binding sites, MqsA binding to the promoter and binding to MqsR are mutually exclusive, resulting in operon derepression when there is more MqsR than MqsA.

In some cases, inhibition of the TA system depends on the molar ratio between toxin and antitoxin. When the molar ratio of toxin to antitoxin is in the right proportion, for example in the Phd/Doc system the ratio of toxin to antitoxin is about 1:1, the antitoxin-toxin complex binds tightly to the DNA. Excessive toxins can induce the formation of saturated complexes and release inhibition of the TA system. When toxin levels exceed antitoxin levels, inhibition is relieved, allowing the antitoxin to be transcribed and translated from scratch. This negative feedback loop is called “conditional synergy.”⁷³ Similarly, in the CcdAB system, the low binding affinity between the antitoxin and the operon alone does not effectively inhibit transcription in the TA system, and the addition of the toxin enhances the binding of the antitoxin to the operon and the inhibitory effect. When the toxin is re-increased, it leads to structural changes in the TA complex and introduces spatial site resistance thereby activating transcription of the TA system. In the RelBE system, two RelB dimers bind synergistically to adjacent sites on the operon, and two RelB dimers flanking each other can each bind a RelE monomer to form a complex that further stabilizes RelB binding to the operon. Excessive amounts of RelE disrupt the contact between neighboring RelB dimers and spatially impede the binding of RelB to the DNA, thereby activating transcription.⁷⁴

Typically, the antitoxin gene is located upstream of the toxin gene, but in some TA systems the antitoxin gene is located downstream of the toxin gene, and such TA systems with reversed gene order include the HicAB system, where the HicAB system consists of two promoters that turn on transcription.⁷⁵ The upstream promoter allows expression of toxin and antitoxin genes, contains a Sxy-dependent cyclic adenosine receptor protein binding site, and is activated by Sxy, and the downstream promoter is repressed by HicB, and this repression can be lifted when HicA is in excess. This mechanism permits the production of more antitoxin when the ratio of toxin to antitoxin is too high.

This complex regulatory network demonstrates the multiple mechanisms employed by the TA system in maintaining the delicate balance between toxins and antitoxins, highlighting the adaptability and complexity of this genetic module.

Biological Role of the Type II TA System in *E. coli*

In *E. coli*, most TAs are located on the chromosome including (*PrfFyhaV*, *MazEF*, *MqsRA*, *ChpBIK*, *DinJyafQ*, *HicAB*, *YafNO*, *RelBrelE*, *yefMyoeB*, and *HipAB*) and five plasmid loci (*PemKI*, *CcdAB*, *VagCD*, *Phd/Doc*, and *ParDE*). The toxin activity leads to plasmid addiction to the cell; hence, the plasmid-encoded TA system is known as the plasmid addiction module (Figure 3a). The chromosomal TA system of bacteria is involved in various biological processes such as stress response,⁷⁶ biofilm formation,⁷⁷ phage inhibition,⁷⁸ virulence⁷⁹ and persistence.⁸⁰

TA Systems and Their Role in Persistence

Bacterial persistence refers to the presence of rare cells insensitive to antibiotics even in fast-growing bacterial populations. It is a phenomenon that causes bacterial cells to resist multiple antibiotics and other environmental damage⁸¹ (Figure 3b). This phenomenon was first discovered by Bigger in 1944 when he was researching how penicillin kills *Staphylococcus aureus*, and he discovered that penicillin often fails to sterilize exponentially growing cells. He correctly hypothesized that persistent bacteria escape killing by antibiotics because they are in a slow-growing or dormant state.⁸² The first link between persistence and the TA module was established when Moyed & Bertrand⁸³ discovered the presence of highly persistent mutations in *HipAB*. *HipA*, a gene encoding a protein of 440 amino acids, is located in the terminal region of the *E. coli* chromosome at 34.3.^{84,85} *HipA* is preceded by *hib* (88 codons), and *HipB* is a dimer that represses transcription through its helix-turn-helix structural domain that binds synergistically to the four operators of the *HipAB* promoter region,⁸⁶ and toxin *HipA* is a serine/threonine kinase that is partially phosphorylated in vivo and autophosphorylated in vitro.^{87,88} It phosphorylates and inhibits the activity of *GltX* (glutamine- tRNA




Figure 3 Shows the rationale for the role of TA modules in their biological functions. (a) Post-isolation killing mechanism, type II system-mediated plasmid addiction relies on differential stabilization between toxin (red) and antitoxin (green) proteins. When the unstable antitoxin is no longer replenished, the toxin will be released from the antitoxin-toxin complex. It will be able to kill these cells, thus contributing to plasmid maintenance. (b) In abortive infection, in phage-infected cells, transcription of host genes is repressed, the unstable antitoxin is not replenished, and the toxin will be released from the antitoxin-toxin complex and be able to prevent phage multiplication. (c) Persister formation, where persisters constitute a subpopulation of cells in the bacterial population that exhibit tolerance to antibiotics and other environmental stress conditions due to a phenotypic shift to a dormant state.

synthetase),^{89,90} thereby reducing the amount of glutamine tRNA in the cell. The lack of glutamine-tRNA in cells triggers an increase in ppGpp (p), leading to the activation of more toxin-antitoxin modules, which are required for the HipA-induced persistence phenotype.⁸¹ Mild overproduction of HipA at levels that do not impair cell growth results in increased levels of persistent protein.^{91,92} HipA mutations have been shown to accumulate over time in clinical isolates of *E. coli* from patients with recurrent urinary tract infections.⁹³ In addition to these gain-of-function mutations, in many cases, artificial overexpression of the toxin results in elevated levels of persistence.⁹⁴

Another related to persistence is the RelBE family, with the RelBE locus in *E. coli* encoding the antitoxin RelB and the toxin RelE. RelE belongs to a well-described superfamily of toxins with many homologs in both bacteria and archaea.⁹⁵ RelE is a ribonuclease that cleaves mRNA located at the ribosomal a-site between the second and third bases of the codon at the a-site.⁴⁰ RelB automatically regulates the transcription of the RelBE operon by combining the two operator sequences of the RelBE promoter region.^{96,97} *E. coli* K-12 encodes six RelBE-like loci.^{48,49,98–100} Several RelBE-like genes (for example, *mqsR* and *yoeB*) have been used to define the RelBE subfamily, and MqsRA and YafQ are shown to be associated with persistence.^{101–103} Under non-stress conditions, the antitoxin MqsA regulates the general stress response by repressing the *rpoS* promoter. As MqsA is degraded by Lon, environmental stresses lead to decreased levels of MqsA, resulting in increased levels of RpoS, which increases biofilm formation and persistence.¹⁰⁴ In addition, it has been shown that the deletion of five or more type II toxin-antitoxin modules in *E. coli* results in reduced formation of holdout bacteria during exponential growth in enriched media.^{105,106}

In addition, mathematical modeling indicated that the TA system is uniquely characterized by two distinct bacterial populations: a dormant population and a fast-growing type.¹⁰⁷ To put it simply, when the concentration of a toxin exceeds a certain threshold, the cell enters a state of continuous survival. How is this state achieved in a growing population of cells? One possibility is that certain cells, where nutrients are locally available, experience a state of micro starvation. This causes an increase in (p)ppGpp levels, which activates Lon protease and leads to antitoxin degradation. The result is a shift from low to high TA ratios, allowing the currently free toxins to begin to exert their toxic effects. However, while we have explained how cells enter the holding state at the molecular level, the molecular mechanisms that allow them to leave the holding state are still unclear. More importantly, recent studies have suggested that the type II TA system may utilize a phenomenological retention mechanism known as “conditional synergism”.⁷³

Stress Response and Biofilm Formation

Biofilms are formed in aquatic environments through bacterial attachment to underwater surfaces, air–liquid interfaces, and each other. Biofilms attach via appendages such as hyphae,^{108,109} flagella,¹¹⁰ and microcolonies are formed from microbial products including polysaccharides,¹¹⁰ glycoproteins, and DNA.^{111,112} *E. coli* biofilms form in the gastro-intestinal tract and bladder of the human host. The pathogenic *E. coli* cause urinary tract infections, including cystitis (bladder infection) and pyelonephritis (kidney infection). The first TA system found to be associated with biofilm formation was the MqsRA system of *E. coli*, consisting of the MqsR toxin with the MqsA antitoxin. MqsR toxin is an RNase⁴⁹ that cleaves mRNA at the GUC site and requires the proteases Lon and ClpXP for its toxicity,¹¹³ and the MqsA antitoxin binds to the toxin through its N-terminal structural domain and to DNA through the helix-turn-helix (HTH) motif in its C-terminal structural domain.⁹⁸ MqsR was induced in a transcriptomic study that identified differentially regulated genes in biofilm cells. In *E. coli*, it is predominantly curli,^{114–116} which promotes biofilm formation, and the gene *csgD* is required for the secretion of curli fibers to the bacterial membrane surface. It has been shown that when well nourished, MqsA increases motility by increasing FlhD (a major regulator of motility) partly through *rpoS31* inhibition and partly through *csgD* inhibition and that under stressful conditions, MqsA is degraded by proteolytic enzymes,¹⁰⁴ and MqsR is activated.¹¹⁷ Degradation of MqsA leads to the de-suppression of RPO and *csgD*, as well as inhibition of FlhD, which subsequently increases biofilm.

The RelBE locus of *E. coli* encodes the RelE toxin and the RelB antitoxin. RelE is an mRNA enzyme that cleaves mRNA,¹¹⁸ located at the ribosomal A site, including its mRNA, while RelB inactivates RelE by forming a tight complex with it. RelB is a metabolically unstable protein, whereas RelE is stable.¹¹⁹ RelB can counteract RelE activity through protein–protein interactions. RelB also inhibits RelBE transcription, and RelE serves as a co-inhibitor of RelBE transcription.¹²⁰ It was shown that RelE encodes an integral translational repressor that is activated during amino acid

(aa) starvation. RelBE promoter is strongly activated during aa starvation, RelBE reduces the rate of post-starvation translation in amino acid-deficient *E. coli* wild-type cells, and glucose starvation induces RelBE transcription, suggesting a possible generalized role for RelBE during nutrient limitation. Induction of transcription occurs independently of RelA and SpoT and is instead dependent on Lon protease.¹¹⁹

The well-studied MazEF system is the first system described to regulate and be responsible for bacterial programmed cell death. MazF encodes the stabilizing toxin, MazF, and MazE encodes the unstable antitoxin, MazE. ATP-dependent ClpPA serine proteases can degrade MazE. MazF is a ribonucleic acid endonuclease that cleaves the mRNAs on the ACA sequence in a ribosome-independent manner.^{7,121} When MazE is co-expressed with MazF, MazE counteracts the toxic activity of MazF, and since MazE is an unstable protein, constant production of MazE is necessary to prevent MazF from exerting itself. Therefore, in some stressful situations, if the expression of the MazEF module on the chromosome is impeded, the amount of MazE in the cell is reduced thus allowing the MazF toxin to be released. Examples include antibiotics that inhibit transcription and translation such as rifampicin, chloramphenicol, and macrolide and DNA damage induced by methotrexate or nalidixic acid. It was found these antibiotics and other stress conditions known to cause bacterial cell death act through the MazEF module.¹²²

Defense Against Phage Infection

Bacteria are often infected by many phages, and host bacteria have evolved diverse molecular strategies in the race with phages, one of which is abortive infection (Abi). In TA-mediated abortive infection, phage infection triggers loss of antitoxin or release of toxin from the toxin-antitoxin complex, which inhibits phage multiplication (Figure 3c) by inhibiting basic cellular processes leading to toxin-mediated bacterial growth arrest.¹²³

In 2004, Hazan and Engelberg-Kulka et al demonstrated that the type II chromosome MazF/MazE system inhibits phage P1.¹²⁴ MazEF TA is located on the *relA* operon and has all the characteristics of an “addiction module”, including the ability to cause cell death. It was demonstrated that the *E. coli* MazEF system prevents phage P1 from entering its lysogenic phase. This phage exclusion is due to the activation of an altruistic cell death program that prevents phage propagation and thus protects the bacterial culture, additionally, the absence of MazEF produces more P1 phages; thus, the phage exclusion phenotype was validated without overproduction of this TA system. In a study by Abdullaheem M. Alawneh et al, it was demonstrated that the growth of T4 phage was significantly increased by disruption of MazE-MazF. Moreover, MazF was ribosylated by the T4 Alt protein ADP immediately after infection, and this modification led to a decrease in MazF RNA cleavage activity, which is the first example of chemical modification of a toxin to regulate its activity.¹²⁵ It has been reported that, in *E. coli* MC4100 and JM109, MazEF-containing cells produce 10–15-fold fewer phages after induction or infection with the mild phage p1. However, no clear data is reporting the mechanism of MazF activation, and a recent study was unable to reproduce these preliminary findings in *E. coli* K12.¹²⁶

In 2011, the type II RnlA/RnlB system was shown to inhibit T4 phages in *E. coli*.¹²⁷ In most TA systems, the antitoxin genes are located upstream of their cognate toxin genes. Unlike most type II TA systems where the toxin genes are in the reverse order of the antitoxin genes, the RnlA/RnlB system provides T4 phages deficient for the gene *dmd*. A strong defense against the *dmd* phage, while the aggregation efficiency of the *dmd* phage was reduced 1000–10,000-fold on *rnlAN*-containing strains.^{128,129} Yonesaki et al initially identified the T4 gene *dmd* as necessary to stabilize mRNAs expressed late in T4 development.¹³⁰ Infection with the T4 *dmd* mutant results in rapid degradation of the antitoxin RnlB, which may lead to the release of the RnlA ribonuclease toxin.¹²⁷ RnlB is also rapidly degraded in a Lon and ClpX-dependent manner in uninfected cells. Because RnlB is intrinsically unstable, T4 infection-induced shutdown of host transcription, including that of RnlAB, may allow the release of active RnlA because RnlB cannot be replenished. When activated upon infection by the T4 *dmd* mutant, the RnlA toxin cleaves phage RNA,^{130,131} although the sequence specificity of RnlA remains uncertain. Another twist to the RnlA system is that RnlA activity is somewhat dependent on host-encoded RNaseHI, which degrades RNA-DNA hybrids.^{132,133} Indeed, the finding that RNaseHI promotes T4 infection upon RnlA activity and inhibition of RnlA by RnlB, possibly through direct interactions, but how RNaseHI affects the RnlAB system remains to be elucidated.

Recent bioinformatics analyses indicate that DarTG family members of TA systems are frequently encoded in defense islands, leading to the prediction that these systems are phage defense elements. Although *E. coli* K-12 does not encode

any DarTG homologs, representatives of two different subfamilies DarTG1 and DarTG2 from environmental *E. coli* isolates strongly protect *E. coli* MG1655 against different phages.¹³⁴ During phage infection, infection with RB69 or T5 phage, respectively, triggers the release of DarT toxin from both the DarTG1 and DarTG2 systems, followed by ADP-ribosylation of phage DNA. This modification results in the inhibition of DNA synthesis and, to a lesser extent, RNA synthesis, which prevents phages from generating viable progeny. In addition, DarG antitoxins were shown to possess ADP-glycohydrolase activity, which allowed them to enzymatically reverse modifications made by their cognate DarT toxin.¹³⁵ In addition, phages that have evolved to overcome the DarTG defense by mutations in their DNA polymerase or the anti-DarT factor gp61.2 encoded by many T-even phages were isolated.¹³⁶

Interestingly, phages have developed many mechanisms to combat abortive infections by interfering with TA module induction or function. For example, phage T4 encodes a “master key” antitoxin that inactivates several RnIA family toxins, and the ADP-ribosyl transferase Alt inhibits the type II toxin MazF in *E. coli*. Phages that often contain specific protease inhibitors that interfere with the degradation of protein antitoxins, thereby attenuating abortive infections of the type II TA module more indirectly.^{123,131}

While some studies have shown that TA systems can and do prevent phage predation, it is not clear whether most TA systems play such a role. Notably, the RnIAB system only protects phages lacking dmd T4 phage, so other *E. coli* phage defense systems likely overcome the existing TA system in *E. coli* k12. Alternatively, the TA system may only protect a very narrow phage spectrum and is used for the great diversity of phages. Some of the phages defended against by individual TA systems in *E. coli* k12 may not have been identified or tested yet. Studies are needed to further explore and characterize the role of TA systems in phage defense. How TA systems impede phage replication and development also requires further investigation.

Conclusion Remarks

This paper focuses on the modulation and biological functions of the type II toxin-antitoxin system in *E. coli*. Despite 40 years of research on the TA system, and many questions remain unanswered. For example, there is still some ambiguity regarding biological function; the model describing how the toxin-antitoxin module leads to persistence formation through (p)ppGpp signaling is an attractive one; however, there is evidence that the toxin-antitoxin module is not the only factor contributing to persistent cell formation. The deletion of multiple toxin-antitoxin modules or the deletion of (p)ppGpp leads to a reduction in the number of persister cells. Still, neither eliminates the presence of persister cells. Deletion of 10 TA motifs in *E. coli* suggested a role in persistent formation, but subsequent reassessment did not support this conclusion. This problem may be attributed to infection by hidden phages.¹³⁷ Similarly, in another study, persister cell formation was not directly related to the TA module.¹³⁸ Thus, there is still a lot of debate about the role of the TA module in bacterial physiology, and it is necessary to carry out more extensive and precise experiments that should be conducted to further reveal the biological function of TA.

With the development of toxin-antitoxin systems, exploring how these systems move between replicons and bacterial species and what drives their evolutionary success is necessary. A better understanding of the mechanisms behind bacterial toxin-antitoxins may lead to the design of drugs that can combat chronic and recurrent infections. In addition, combining TA systems with other biological systems to develop novel bioregulatory elements will also hold promise in the field of synthetic biology.

Data Sharing Statement

No data was used for the research described in the article.

Ethical Statement

This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Funding

This research was funded by the Project of the key R & D program of the 2022 year of Ningbo Science and Technology Bureau (2022z2202022), Key Project of Ningbo Municipal Science and Technology Bureau (2023j020), China Population Welfare Foundation Medical Innovation Project-Comparative Study on the Comprehensive Effectiveness of Artificial Intelligence Blood Collection Robots and Manual Blood Collection in Clinical Blood Collection Practice (SLB-6-20230912-351), Ningbo Medical Science and Technology Program Project (2022Y05) and Faculty-level Project of the First Hospital Affiliated to Ningbo University (XGY2308).

Disclosure

The authors declare no conflicts of interest.

References

- Jurėnas D, Fraikin N, Goormaghtigh F, Van Melderen L. Biology and evolution of bacterial toxin-antitoxin systems. *Nat Rev Microbiol*. 2022;20(6):335–350. doi:10.1038/s41579-021-00661-1
- Srivastava A, Pati S, Kaushik H, Singh S, Garg LC. Toxin-antitoxin systems and their medical applications: current status and future perspective. *Appl Microbiol Biotechnol*. 2021;105(5):1803–1821. doi:10.1007/s00253-021-11134-z
- Ogura T, Hiraga S. Mini-F plasmid genes that couple host cell division to plasmid proliferation. *Proc Natl Acad Sci USA*. 1983;80(15):4784–4788. doi:10.1073/pnas.80.15.4784
- Dai Z, Wu T, Xu S, et al. Characterization of toxin-antitoxin systems from public sequencing data: a case study in *Pseudomonas aeruginosa*. *Front Microbiol*. 2022;13:951774. doi:10.3389/fmicb.2022.951774
- Gerdes K, Christensen SK, Løbner-Olesen A. Prokaryotic toxin-antitoxin stress response loci. *Nat Rev Microbiol*. 2005;3(5):371–382. doi:10.1038/nrmicro1147
- Pandey DP, Gerdes K. Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. *Nucleic Acids Res*. 2005;33(3):966–976. doi:10.1093/nar/gki201
- Kim DH, Kang SM, Baek SM, et al. Role of PemI in the *Staphylococcus aureus* PemIK toxin-antitoxin complex: pemI controls PemK by acting as a PemK loop mimic. *Nucleic Acids Res*. 2022;50(4):2319–2333. doi:10.1093/nar/gkab1288
- Gerdes K, Helin K, Christensen OW, Løbner-Olesen A. Translational control and differential RNA decay are key elements regulating postsegregational expression of the killer protein encoded by the parB locus of plasmid R1. *J Mol Biol*. 1988;203(1):119–129. doi:10.1016/0022-2836(88)90096-4
- Kawano M, Oshima T, Kasai H, Mori H. Molecular characterization of long direct repeat (LDR) sequences expressing a stable mRNA encoding for a 35-amino-acid cell-killing peptide and a cis-encoded small antisense RNA in *Escherichia coli*. *Mol Microbiol*. 2002;45(2):333–349. doi:10.1046/j.1365-2958.2002.03042.x
- Darfeuille F, Unoson C, Vogel J, Wagner EG. An antisense RNA inhibits translation by competing with standby ribosomes. *Mol Cell*. 2007;26(3):381–392. doi:10.1016/j.molcel.2007.04.003
- Kawano M, Aravind L, Storz G. An antisense RNA controls synthesis of an SOS-induced toxin evolved from an antitoxin. *Mol Microbiol*. 2007;64(3):738–754. doi:10.1111/j.1365-2958.2007.05688.x
- Fozo EM, Kawano M, Fontaine F, et al. Repression of small toxic protein synthesis by the Sib and OhsC small RNAs. *Mol Microbiol*. 2008;70(5):1076–1093. doi:10.1111/j.1365-2958.2008.06394.x
- Van Gundy T, Martin E, Bono J, Hatton O, Lybecker MC. An antisense RNA fine-tunes gene expression of the Type II MazEF toxin-antitoxin system. *mBio*. 2022;13(1):e0344321. doi:10.1128/mbio.03443-21
- Tam JE, Kline BC. The F plasmid ccd autorepressor is a complex of CcdA and CcdB proteins. *Mol Gen Genet*. 1989;219(1–2):26–32. doi:10.1007/bf00261153
- Lehnherr H, Maguin E, Jafri S, Yarmolinsky MB. Plasmid addiction genes of bacteriophage P1: doc, which causes cell death on curing of prophage, and phd, which prevents host death when prophage is retained. *J Mol Biol*. 1993;233(3):414–428. doi:10.1006/jmbi.1993.1521
- Li GY, Zhang Y, Inouye M, Ikura M. Inhibitory mechanism of *Escherichia coli* RelE-RelB toxin-antitoxin module involves a helix displacement near an mRNA interferase active site. *J Biol Chem*. 2009;284(21):14628–14636. doi:10.1074/jbc.M809656200
- Jurėnas D, Van Melderen L, Garcia-Pino A. Mechanism of regulation and neutralization of the AtaR-AtaT toxin-antitoxin system. *Nat Chem Biol*. 2019;15(3):285–294. doi:10.1038/s41589-018-0216-z
- Bonini AA, Maggi S, Mori G, et al. Functional characterization and transcriptional repression by *Lactocaseibacillus paracasei* DinJ-YafQ. *Appl Microbiol Biotechnol*. 2022;106(21):7113–7128. doi:10.1007/s00253-022-12195-4
- Samson JE, Spinelli S, Cambillau C, Moineau S. Structure and activity of AbiQ, a lactococcal endoribonuclease belonging to the type III toxin-antitoxin system. *Mol Microbiol*. 2013;87(4):756–768. doi:10.1111/mmi.12129
- Short FL, Pei XY, Blower TR, et al. Selectivity and self-assembly in the control of a bacterial toxin by an antitoxic noncoding RNA pseudoknot. *Proc Natl Acad Sci USA*. 2013;110(3):E241–9. doi:10.1073/pnas.1216039110
- Sarpong DD, Murphy ER. RNA regulated toxin-antitoxin systems in pathogenic bacteria. *Front Cell Infect Microbiol*. 2021;11:661026. doi:10.3389/fcimb.2021.661026
- Jimmy S, Saha CK, Kurata T, et al. A widespread toxin-antitoxin system exploiting growth control via alarmone signaling. *Proc Natl Acad Sci USA*. 2020;117(19):10500–10510. doi:10.1073/pnas.1916617117
- Jankevicius G, Ariza A, Ahel M, Ahel I. The toxin-antitoxin system DarTG catalyzes reversible ADP-ribosylation of DNA. *Mol Cell*. 2016;64(6):1109–1116. doi:10.1016/j.molcel.2016.11.014

24. Wang X, Lord DM, Cheng HY, et al. A new type V toxin-antitoxin system where mRNA for toxin GhoT is cleaved by antitoxin GhoS. *Nat Chem Biol.* 2012;8(10):855–861. doi:10.1038/nchembio.1062
25. Jin C, Kang SM, Kim DH, Lee BJ. Structural and functional analysis of the *Klebsiella pneumoniae* MazEF toxin-antitoxin system. *IUCrJ.* 2021;8(Pt 3):362–371. doi:10.1107/s2052252521000452
26. Aakre CD, Phung TN, Huang D, Laub MT. A bacterial toxin inhibits DNA replication elongation through a direct interaction with the β sliding clamp. *Mol Cell.* 2013;52(5):617–628. doi:10.1016/j.molcel.2013.10.014
27. Songailiene I, Juozapaitis J, Tamulaitiene G, et al. HEPN-MNT toxin-antitoxin system: the HEPN ribonuclease is neutralized by OligoAMPylation. *Mol Cell.* 2020;80(6):955–970.e7. doi:10.1016/j.molcel.2020.11.034
28. Marimon O, Teixeira JM, Cordeiro TN, et al. An oxygen-sensitive toxin-antitoxin system. *Nat Commun.* 2016;7:13634. doi:10.1038/ncomms13634
29. Yu X, Gao X, Zhu K, et al. Characterization of a toxin-antitoxin system in *Mycobacterium tuberculosis* suggests neutralization by phosphorylation as the antitoxicity mechanism. *Commun Biol.* 2020;3(1):216. doi:10.1038/s42003-020-0941-1
30. Li M, Gong L, Cheng F, et al. Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systems. *Science.* 2021;372(6541). doi:10.1126/science.abe5601
31. Choi JS, Kim W, Suk S, et al. The small RNA, SdsR, acts as a novel type of toxin in *Escherichia coli*. *RNA Biol.* 2018;15(10):1319–1335. doi:10.1080/15476286.2018.1532252
32. Sevin EW, Barloy-Hubler F. RASTA-Bacteria: a web-based tool for identifying toxin-antitoxin loci in prokaryotes. *Genome Biol.* 2007;8(8):R155. doi:10.1186/gb-2007-8-8-r155
33. Song Y, Zhang S, Ye Z, et al. The novel type II toxin-antitoxin PacTA modulates *Pseudomonas aeruginosa* iron homeostasis by obstructing the DNA-binding activity of Fur. *Nucleic Acids Res.* 2022;50(18):10586–10600. doi:10.1093/nar/gkac867
34. Shao Y, Harrison EM, Bi D, et al. TADB: a web-based resource for Type 2 toxin-antitoxin loci in bacteria and archaea. *Nucleic Acids Res.* 2011;39(Database issue):D606–11. doi:10.1093/nar/gkq908
35. Leplae R, Geeraerts D, Hallez R, Guglielmini J, Drèze P, Van Melderen L. Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search and functional analysis of novel families. *Nucleic Acids Res.* 2011;39(13):5513–5525. doi:10.1093/nar/gkr131
36. Fiedoruk K, Daniluk T, Swiecicka I, Sciepek M, Leszczynska K. Type II toxin-antitoxin systems are unevenly distributed among *Escherichia coli* phylogroups. *Microbiology.* 2015;161(Pt 1):158–167. doi:10.1099/mic.0.082883-0
37. Sun C, Guo Y, Tang K, et al. MqsR/MqsA toxin/antitoxin system regulates persistence and biofilm formation in *Pseudomonas putida* KT2440. *Front Microbiol.* 2017;8:840. doi:10.3389/fmicb.2017.00840
38. Afif H, Allali N, Couturier M, Van Melderen L. The ratio between CcdA and CcdB modulates the transcriptional repression of the ccd poison-antidote system. *Mol Microbiol.* 2001;41(1):73–82. doi:10.1046/j.1365-2958.2001.02492.x
39. Xue L, Yue J, Ke J, et al. Distinct oligomeric structures of the YoeB-YefM complex provide insights into the conditional cooperativity of type II toxin-antitoxin system. *Nucleic Acids Res.* 2020;48(18):10527–10541. doi:10.1093/nar/gkaa706
40. Neubauer C, Gao YG, Andersen KR, et al. The structural basis for mRNA recognition and cleavage by the ribosome-dependent endonuclease RelE. *Cell.* 2009;139(6):1084–1095. doi:10.1016/j.cell.2009.11.015
41. Christensen SK, Gerdes K. RelE toxins from bacteria and Archaea cleave mRNAs on translating ribosomes, which are rescued by tmRNA. *Mol Microbiol.* 2003;48(5):1389–1400. doi:10.1046/j.1365-2958.2003.03512.x
42. Abril AG, Quintela-Balaja M, Villa TG, Calo-Mata P, Barros-Velázquez J, Carrera M. Proteomic Characterization of virulence factors and related proteins in enterococcus strains from dairy and fermented food products. *Int J Mol Sci.* 2022;23(18). doi:10.3390/ijms231810971
43. Feng S, Chen Y, Kamada K, et al. YoeB-ribosome structure: a canonical RNase that requires the ribosome for its specific activity. *Nucleic Acids Res.* 2013;41(20):9549–9556. doi:10.1093/nar/gkt742
44. Maehigashi T, Ruangprasert A, Miles SJ, Dunham CM. Molecular basis of ribosome recognition and mRNA hydrolysis by the *E. coli* YafQ toxin. *Nucleic Acids Res.* 2015;43(16):8002–8012. doi:10.1093/nar/gkv791
45. Zhang Y, Yamaguchi Y, Inouye M. Characterization of YafO, an *Escherichia coli* toxin. *J Biol Chem.* 2009;284(38):25522–25531. doi:10.1074/jbc.M109.036624
46. Hurley JM, Woychik NA. Bacterial toxin HigB associates with ribosomes and mediates translation-dependent mRNA cleavage at A-rich sites. *J Biol Chem.* 2009;284(28):18605–18613. doi:10.1074/jbc.M109.008763
47. Schureck MA, Maehigashi T, Miles SJ, et al. Structure of the *Proteus vulgaris* HigB-(HigA)2-HigB toxin-antitoxin complex. *J Biol Chem.* 2014;289(2):1060–1070. doi:10.1074/jbc.M113.512095
48. Christensen-Dalsgaard M, Jørgensen MG, Gerdes K. Three new RelE-homologous mRNA interferases of *Escherichia coli* differentially induced by environmental stresses. *Mol Microbiol.* 2010;75(2):333–348. doi:10.1111/j.1365-2958.2009.06969.x
49. Yamaguchi Y, Park JH, Inouye M. MqsR, a crucial regulator for quorum sensing and biofilm formation, is a GCU-specific mRNA interferase in *Escherichia coli*. *J Biol Chem.* 2009;284(42):28746–28753. doi:10.1074/jbc.M109.032904
50. Yu V, Ronzone E, Lord D, Peti W, Page R. MqsR is a noncanonical microbial RNase toxin that is inhibited by antitoxin MqsA via steric blockage of substrate binding. *J Biol Chem.* 2022;298(11):102535. doi:10.1016/j.jbc.2022.102535
51. Yamaguchi Y, Regulation of growth and death in *Escherichia coli* by toxin-antitoxin systems. *Nat Rev Microbiol.* 2011;9(11):779–790. doi:10.1038/nrmicro2651
52. Garcia-Rodriguez G, Charlier D, Wilmaerts D, Michiels J, Loris R. Alternative dimerization is required for activity and inhibition of the HEPN ribonuclease RnIA. *Nucleic Acids Res.* 2021;49(12):7164–7178. doi:10.1093/nar/gkab513
53. Cruz JW, Rothenbacher FP, Maehigashi T, Lane WS, Dunham CM, Woychik NA. Doc toxin is a kinase that inactivates elongation factor Tu. *J Biol Chem.* 2014;289(11):7788–7798. doi:10.1074/jbc.M113.544429
54. Jiang Y, Pogliano J, Helinski DR, Konieczny I. ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of *Escherichia coli* gyrase. *Mol Microbiol.* 2002;44(4):971–979. doi:10.1046/j.1365-2958.2002.02921.x
55. Agüero JA, Akarsu H, Aguilar-Bultet L, Oevermann A, Falquet L. Large-scale comparison of toxin and antitoxins in *Listeria monocytogenes*. *Toxins.* 2020;12(1). doi:10.3390/toxins12010029
56. Gupta K, Tripathi A, Sahu A, Varadarajan R. Contribution of the chromosomal ccdAB operon to bacterial drug tolerance. *J Bacteriol.* 2017;199(19). doi:10.1128/jb.00397-17

57. Harms A, Stanger FV, Scheu PD, et al. Adenylation of Gyrase and Topo IV by FicT toxins disrupts bacterial DNA topology. *Cell Rep.* **2015**;12(9):1497–1507. doi:10.1016/j.celrep.2015.07.056
58. Mets T, Kasvandik S, Saarma M, Ü M, Tenson T, Kaldalu N. Fragmentation of *Escherichia coli* mRNA by MazF and MqsR. *Biochimie.* **2019**;156:79–91. doi:10.1016/j.biochi.2018.10.004
59. Cintrón M, Zeng JM, Barth VC, Cruz JW, Husson RN, Woychik NA. Accurate target identification for Mycobacterium tuberculosis endoribonuclease toxins requires expression in their native host. *Sci Rep.* **2019**;9(1):5949. doi:10.1038/s41598-019-41548-9
60. Vang Nielsen S, Turnbull KJ, Roghanian M, et al. Serine-threonine kinases encoded by split hipA homologs inhibit tryptophanyl-tRNA synthetase. *mBio.* **2019**;10(3). doi:10.1128/mBio.01138-19
61. Freire DM, Gutierrez C, Garza-Garcia A, et al. An NAD(+) phosphorylase toxin triggers mycobacterium tuberculosis cell death. *Mol Cell.* **2019**;73(6):1282–1291.e8. doi:10.1016/j.molcel.2019.01.028
62. Meinhardt A, Alonso JC, Sträter N, Saenger W. Crystal structure of the plasmid maintenance system epsilon/zeta: functional mechanism of toxin zeta and inactivation by epsilon 2 zeta 2 complex formation. *Proc Natl Acad Sci USA.* **2003**;100(4):1661–1666. doi:10.1073/pnas.0434325100
63. Khoo SK, Loll B, Chan WT, et al. Molecular and structural characterization of the PezAT chromosomal toxin-antitoxin system of the human pathogen *Streptococcus pneumoniae*. *J Biol Chem.* **2007**;282(27):19606–19618. doi:10.1074/jbc.M701703200
64. Ames JR, Muthuramalingam M, Murphy T, Najar FZ, Bourne CR. Expression of different ParE toxins results in conserved phenotypes with distinguishable classes of toxicity. *MicrobiologyOpen.* **2019**;8(10):e902. doi:10.1002/mbo3.902
65. Jadhav PV, Sinha VK, Chugh S, et al. 2.09 Å resolution structure of *E. coli* HigBA toxin-antitoxin complex reveals an ordered DNA-binding domain and intrinsic dynamics in antitoxin. *Biochem J.* **2020**;477(20):4001–4019. doi:10.1042/bcj20200363
66. Fraikin N, Rousseau CJ, Goeders N, Van Melderen L. Reassessing the role of the type II MqsRA toxin-antitoxin system in stress response and biofilm formation: mqsA is transcriptionally uncoupled from mqsR. *mBio.* **2019**;10(6). doi:10.1128/mBio.02678-19
67. Xu BS, Liu M, Zhou K, et al. Conformational changes of antitoxin HigA from *Escherichia coli* str. K-12 upon binding of its cognate toxin HigB reveal a new regulation mechanism in toxin-antitoxin systems. *Biochem Biophys Res Commun.* **2019**;514(1):37–43. doi:10.1016/j.bbrc.2019.04.061
68. Guo Y, Yao J, Sun C, Wen Z, Wang X. Characterization of the deep-sea *Streptomyces* sp. SCSIO 02999 derived VapC/VapB toxin-antitoxin system in *Escherichia coli*. *Toxins.* **2016**;8(7). doi:10.3390/toxins8070195
69. Koo JS, Kang SM, Jung WM, Kim DH, Lee BJ. The *Haemophilus influenzae* HipBA toxin-antitoxin system adopts an unusual three-component regulatory mechanism. *IUCrJ.* **2022**;9(Pt 5):625–631. doi:10.1107/s205225252200687x
70. Masuda Y, Sakamoto E, Honjoh KI, Miyamoto T. Role of toxin-antitoxin-regulated persister population and indole in bacterial heat tolerance. *Appl Environ Microbiol.* **2020**;86(16). doi:10.1128/aem.00935-20
71. Lee IG, Lee SJ, Chae S, Lee KY, Kim JH, Lee BJ. Structural and functional studies of the Mycobacterium tuberculosis VapBC30 toxin-antitoxin system: implications for the design of novel antimicrobial peptides. *Nucleic Acids Res.* **2015**;43(15):7624–7637. doi:10.1093/nar/gkv689
72. Winter AJ, Williams C, Isupov MN, et al. The molecular basis of protein toxin HicA-dependent binding of the protein antitoxin HicB to DNA. *J Biol Chem.* **2018**;293(50):19429–19440. doi:10.1074/jbc.RA118.005173
73. Lima-Mendez G, Oliveira Alvarenga D, Ross K, et al. Toxin-antitoxin gene pairs found in Tn3 family transposons appear to be an integral part of the transposition module. *mBio.* **2020**;11(2). doi:10.1128/mBio.00452-20
74. Bøggild A, Sofos N, Andersen KR, et al. The crystal structure of the intact *E. coli* RelBE toxin-antitoxin complex provides the structural basis for conditional cooperativity. *Structure.* **2012**;20(10):1641–1648. doi:10.1016/j.str.2012.08.017
75. Turnbull KJ, Gerdes K. HicA toxin of *Escherichia coli* derepresses hicAB transcription to selectively produce HicB antitoxin. *Mol Microbiol.* **2017**;104(5):781–792. doi:10.1111/mmi.13662
76. Hazan R, Sat B, Engelberg-Kulka H. *Escherichia coli* mazEF-mediated cell death is triggered by various stressful conditions. *J Bacteriol.* **2004**;186(11):3663–3669. doi:10.1128/jb.186.11.3663-3669.2004
77. Ma D, Mandell JB, Donegan NP, et al. The toxin-antitoxin MazEF drives *Staphylococcus aureus* biofilm formation, antibiotic tolerance, and chronic infection. *mBio.* **2019**;10(6). doi:10.1128/mBio.01658-19
78. Pecota DC, Wood TK. Exclusion of T4 phage by the hok/sok killer locus from plasmid R1. *J Bacteriol.* **1996**;178(7):2044–2050. doi:10.1128/jb.178.7.2044-2050.1996
79. Brown JS, Gilliland SM, Spratt BG, Holden DW. A locus contained within a variable region of pneumococcal pathogenicity island 1 contributes to virulence in mice. *Infect Immun.* **2004**;72(3):1587–1593. doi:10.1128/iai.72.3.1587-1593.2004
80. Rycroft JA, Gollan B, Grabe GJ, et al. Activity of acetyltransferase toxins involved in *Salmonella* persister formation during macrophage infection. *Nat Commun.* **2018**;9(1):1993. doi:10.1038/s41467-018-04472-6
81. Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. *Nat Rev Microbiol.* **2017**;15(8):453–464. doi:10.1038/nrmicro.2017.42
82. Bigger. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. *Lancet.* **1944**. doi:10.1016/S0140-6736(00)74210-3
83. Moyed HS, Bertrand KP. hipA, a newly recognized gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol.* **1983**;155(2):768–775. doi:10.1128/jb.155.2.768-775.1983
84. Black DS, Kelly AJ, Mardis MJ, Moyed HS. Structure and organization of Hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. *J Bacteriol.* **1991**;173(18):5732–5739. doi:10.1128/jb.173.18.5732-5739.1991
85. Moyed HS, Broderick SH. Molecular cloning and expression of hipA, a gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol.* **1986**;166(2):399–403. doi:10.1128/jb.166.2.399-403.1986
86. Black DS, Irwin B, Moyed HS. Autoregulation of Hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. *J Bacteriol.* **1994**;176(13):4081–4091. doi:10.1128/jb.176.13.4081-4091.1994
87. Correia FF, D'Onofrio A, Rejtar T, et al. Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in *Escherichia coli*. *J Bacteriol.* **2006**;188(24):8360–8367. doi:10.1128/jb.01237-06
88. Béchon N, Mihajlovic J, Lopes AA, et al. *Bacteroides thetaiotaomicron* uses a widespread extracellular DNase to promote bile-dependent biofilm formation. *Proc Natl Acad Sci USA.* **2022**;119(7). doi:10.1073/pnas.2111228119
89. Germain E, Castro-Roa D, Zenkin N, Gerdes K. Molecular mechanism of bacterial persistence by HipA. *Mol Cell.* **2013**;52(2):248–254. doi:10.1016/j.molcel.2013.08.045

90. Kaspy I, Rotem E, Weiss N, Ronin I, Balaban NQ, Glaser G. HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. *Nat Commun.* **2013**;4:3001. doi:10.1038/ncomms4001
91. Gerdes K, Maisonneuve E. Bacterial persistence and toxin-antitoxin loci. *Annual Rev Microbiol.* **2012**;66:103–123. doi:10.1146/annurev-micro-092611-150159
92. Dhaouadi Y, Hashemi MJ, Ren D. Persistence and culturability of *Escherichia coli* under induced toxin expression. *Antibiotics.* **2024**;13(9). doi:10.3390/antibiotics13090863
93. Van den Bergh B, Fauvart M, Michiels J. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. *FEMS Microbiol Rev.* **2017**;41(3):219–251. doi:10.1093/femsre/fux001
94. Ronneau S, Helaine S. Clarifying the link between toxin-antitoxin modules and bacterial persistence. *J mol Biol.* **2019**;431(18):3462–3471. doi:10.1016/j.jmb.2019.03.019
95. Gerdes K. Toxin-antitoxin modules may regulate synthesis of macromolecules during nutritional stress. *J Bacteriol.* **2000**;182(3):561–572. doi:10.1128/jb.182.3.561-572.2000
96. Overgaard M, Borch J, Gerdes K, RelB and RelE of *Escherichia coli* form a tight complex that represses transcription via the ribbon-helix-helix motif in RelB. *J mol Biol.* **2009**;394(2):183–196. doi:10.1016/j.jmb.2009.09.006
97. Moreno-Córdoba I, Chan WT, Nieto C, Espinosa M. Interactions of the *Streptococcus pneumoniae* toxin-antitoxin RelBE proteins with their target DNA. *Microorganisms.* **2021**;9(4). doi:10.3390/microorganisms9040851
98. Brown BL, Grigoriu S, Kim Y, et al. Three dimensional structure of the MqsR: MqsA complex: a novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties. *PLoS Pathogens.* **2009**;5(12):e1000706. doi:10.1371/journal.ppat.1000706
99. Grady R, Hayes F. Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of *Enterococcus faecium*. *Mol Microbiol.* **2003**;47(5):1419–1432. doi:10.1046/j.1365-2958.2003.03387.x
100. Schmidt O, Schuenemann VJ, Hand NJ, et al. prfF and yhaV encode a new toxin-antitoxin system in *Escherichia coli*. *J Mol Biol.* **2007**;372(4):894–905. doi:10.1016/j.jmb.2007.07.016
101. González Barrios AF, Zuo R, Hashimoto Y, Yang L, Bentley WE, Wood TK. Autoinducer 2 controls biofilm formation in *Escherichia coli* through a novel motility quorum-sensing regulator (MqsR, B3022). *J Bacteriol.* **2006**;188(1):305–316. doi:10.1128/jb.188.1.305-316.2006
102. Harrison JJ, Wade WD, Akierman S, et al. The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for *Escherichia coli* growing in a biofilm. *Antimicrob Agents Chemother.* **2009**;53(6):2253–2258. doi:10.1128/aac.00043-09
103. Spanka DT, Konzer A, Edelmann D, Berghoff BA. High-throughput proteomics identifies proteins with importance to postantibiotic recovery in depolarized persister cells. *Front Microbiol.* **2019**;10:378. doi:10.3389/fmicb.2019.00378
104. Wang X, Kim Y, Hong SH, et al. Antitoxin MqsA helps mediate the bacterial general stress response. *Nat Chem Biol.* **2011**;7(6):359–366. doi:10.1038/nchembio.560
105. Maisonneuve E, Castro-Camargo M, Gerdes K. (p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity. *Cell.* **2018**;172(5):1135. doi:10.1016/j.cell.2018.02.023
106. Chowdhury N, Kwan BW, Wood TK. Persistence increases in the absence of the alarmone guanosine tetraphosphate by reducing cell growth. *Sci Rep.* **2016**;6:20519. doi:10.1038/srep20519
107. Tian C, Semsey S, Mitarai N. Synchronized switching of multiple toxin-antitoxin modules by (p)ppGpp fluctuation. *Nucleic Acids Res.* **2017**;45(14):8180–8189. doi:10.1093/nar/gkx552
108. Müller CM, Aberg A, Strasevičienė J, Emody L, Uhlin BE, Balsalobre C. Type 1 fimbriae, a colonization factor of uropathogenic *Escherichia coli*, are controlled by the metabolic sensor CRP-cAMP. *PLoS Pathogens.* **2009**;5(2):e1000303. doi:10.1371/journal.ppat.1000303
109. Liu Z, Li L, Fang Z, et al. Integration of transcriptome and metabolome reveals the genes and metabolites involved in bifidobacterium bifidum biofilm formation. *Int J Mol Sci.* **2021**;22(14). doi:10.3390/ijms22147596
110. Karatan E, Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. *Microbiol Mol Biol Rev.* **2009**;73(2):310–347. doi:10.1128/mmr.00041-08
111. Barken KB, Pamp SJ, Yang L, et al. Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in *Pseudomonas aeruginosa* biofilms. *Environ Microbiol.* **2008**;10(9):2331–2343. doi:10.1111/j.1462-2920.2008.01658.x
112. Khelissa S, El Fannassi Y, Mechmechani S, et al. Water-soluble ruthenium (II) complex derived from optically pure limonene and its microencapsulation are efficient tools against bacterial food pathogen biofilms: *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, and *Listeria monocytogenes*. *Front Microbiol.* **2021**;12:711326. doi:10.3389/fmicb.2021.711326
113. Kim Y, Wang X, Zhang XS, et al. *Escherichia coli* toxin/antitoxin pair MqsR/MqsA regulate toxin CspD. *Environ Microbiol.* **2010**;12(5):1105–1121. doi:10.1111/j.1462-2920.2009.02147.x
114. Ryu JH, Kim H, Frank JF, Beuchat LR. Attachment and biofilm formation on stainless steel by *Escherichia coli* O157:H7 as affected by curli production. *Lett Appl Microbiol.* **2004**;39(4):359–362. doi:10.1111/j.1472-765X.2004.01591.x
115. Austin JW, Sanders G, Kay WW, Collinson SK. Thin aggregative fimbriae enhance *Salmonella enteritidis* biofilm formation. *FEMS Microbiol Lett.* **1998**;162(2):295–301. doi:10.1111/j.1574-6968.1998.tb13012.x
116. Jonas K, Tomenius H, Kader A, et al. Roles of curli, cellulose and BapA in *Salmonella* biofilm morphology studied by atomic force microscopy. *BMC Microbiol.* **2007**;7:70. doi:10.1186/1471-2180-7-70
117. Kasari V, Mets T, Tenson T, Kaldalu N. Transcriptional cross-activation between toxin-antitoxin systems of *Escherichia coli*. *BMC Microbiol.* **2013**;13:45. doi:10.1186/1471-2180-13-45
118. Pedersen K, Zavialov AV, Pavlov MY, Elf J, Gerdes K, Ehrenberg M. The bacterial toxin RelE displays codon-specific cleavage of mRNAs in the ribosomal A site. *Cell.* **2003**;112(1):131–140. doi:10.1016/s0092-8674(02)01248-5
119. Christensen SK, Mikkelsen M, Pedersen K, Gerdes K. RelE, a global inhibitor of translation, is activated during nutritional stress. *Proc Natl Acad Sci USA.* **2001**;98(25):14328–14333. doi:10.1073/pnas.251327898
120. Gotfredsen M, Gerdes K. The *Escherichia coli* relBE genes belong to a new toxin-antitoxin gene family. *Mol Microbiol.* **1998**;29(4):1065–1076. doi:10.1046/j.1365-2958.1998.00993.x
121. Zhang Y, Zhu L, Zhang J, Inouye M. Characterization of ChpBK, an mRNA interferase from *Escherichia coli*. *J Biol Chem.* **2005**;280(28):26080–26088. doi:10.1074/jbc.M502050200

122. Bezrukov F, Prados J, Renzoni A, Panasenکو OO. MazF toxin causes alterations in *Staphylococcus aureus* transcriptome, translome and proteome that underlie bacterial dormancy. *Nucleic Acids Res.* **2021**;49(4):2085–2101. doi:10.1093/nar/gkaa1292
123. LeRoux M, Laub MT. Toxin-Antitoxin Systems as Phage Defense Elements. *Annual Rev Microbiol.* **2022**;76:21–43. doi:10.1146/annurev-micro-020722-013730
124. Hazan R, Engelberg-Kulka H. *Escherichia coli* mazEF-mediated cell death as a defense mechanism that inhibits the spread of phage P1. *Mol Genet Genom.* **2004**;272(2):227–234. doi:10.1007/s00438-004-1048-y
125. Alawneh AM, Qi D, Yonesaki T, Otsuka Y. An ADP-ribosyltransferase Alt of bacteriophage T4 negatively regulates the *Escherichia coli* MazF toxin of a toxin-antitoxin module. *Mol Microbiol.* **2016**;99(1):188–198. doi:10.1111/mmi.13225
126. Guegler CK, Laub MT. Shutoff of host transcription triggers a toxin-antitoxin system to cleave phage RNA and abort infection. *Mol Cell.* **2021**;81(11):2361–2373.e9. doi:10.1016/j.molcel.2021.03.027
127. Koga M, Otsuka Y, Lemire S, Yonesaki T. *Escherichia coli* rnlA and rnlB compose a novel toxin-antitoxin system. *Genetics.* **2011**;187(1):123–130. doi:10.1534/genetics.110.121798
128. Otsuka Y, Yonesaki T. Dmd of bacteriophage T4 functions as an antitoxin against *Escherichia coli* LsoA and RnlA toxins. *Mol Microbiol.* **2012**;83(4):669–681. doi:10.1111/j.1365-2958.2012.07975.x
129. Srikant S, Guegler CK, Laub MT. The evolution of a counter-defense mechanism in a virus constrains its host range. *eLife.* **2022**; 11:e79549. doi:10.7554/eLife.79549.
130. Otsuka Y, Yonesaki T. A novel endoribonuclease, RNase LS, in *Escherichia coli*. *Genetics.* **2005**;169(1):13–20. doi:10.1534/genetics.104.033290
131. Ni M, Lin J, Gu J, Lin S, He M, Guo Y. Antitoxin CrIA of CrITA toxin-antitoxin system in a clinical isolate *Pseudomonas aeruginosa* inhibits lytic phage infection. *Front Microbiol.* **2022**;13:892021. doi:10.3389/fmicb.2022.892021
132. Naka K, Koga M, Yonesaki T, Otsuka Y. RNase HI stimulates the activity of RnlA toxin in *Escherichia coli*. *Mol Microbiol.* **2014**;91(3):596–605. doi:10.1111/mmi.12479
133. Wang Y, Zhou Y, Shi C, et al. A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria. *Nat Commun.* **2022**;13(1):6434. doi:10.1038/s41467-022-34034-w
134. Schuller M, Raggiaschi R, Mikolcevic P, et al. Molecular basis for the reversible ADP-ribosylation of guanosine bases. *Mol Cell.* **2023**;83(13):2303–2315.e6. doi:10.1016/j.molcel.2023.06.013
135. Patel KM, Seed KD. Sporadic phage defense in epidemic *Vibrio cholerae* mediated by the toxin-antitoxin system DarTG is countered by a phage-encoded antitoxin mimic. *mBio.* **2024**;15(10):e0011124. doi:10.1128/mbio.00111-24
136. LeRoux M, Srikant S, Teodoro GIC, et al. The DarTG toxin-antitoxin system provides phage defence by ADP-ribosylating viral DNA. *Nat Microbiol.* **2022**;7(7):1028–1040. doi:10.1038/s41564-022-01153-5
137. Harms A, Fino C, Sørensen MA, Semsey S, Gerdes K. Prophages and growth dynamics confound experimental results with antibiotic-tolerant persister cells. *mBio.* **2017**;8(6). doi:10.1128/mBio.01964-17
138. Goormaghtigh F, Fraikin N, Putrinš M, et al. Reassessing the role of type II toxin-antitoxin systems in formation of *Escherichia coli* type II persister cells. *mBio.* **2018**;9(3). doi:10.1128/mBio.00640-18

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress
Taylor & Francis Group